Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea.
Chapin AR, Carpenter CM, Dudley WC, Gibson LC, Pratdesaba R, Torres O, Sanchez D, Belkind-Gerson J, Nyquist I, Kärnell A, Gustafsson B, Halpern JL, Bourgeois AL, Schwab KJ. Chapin AR, et al. Among authors: gustafsson b. J Clin Microbiol. 2005 Mar;43(3):1112-7. doi: 10.1128/JCM.43.3.1112-1117.2005. J Clin Microbiol. 2005. PMID: 15750070 Free PMC article.
Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM. Lundgren A, et al. Among authors: gustafsson b. Vaccine. 2013 Feb 6;31(8):1163-70. doi: 10.1016/j.vaccine.2012.12.063. Epub 2013 Jan 7. Vaccine. 2013. PMID: 23306362 Clinical Trial.
Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM. Holmgren J, et al. Among authors: gustafsson b. Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27. Vaccine. 2013. PMID: 23541621 Free article.
Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM. Lundgren A, et al. Among authors: gustafsson b. Vaccine. 2014 Dec 12;32(52):7077-84. doi: 10.1016/j.vaccine.2014.10.069. Epub 2014 Nov 5. Vaccine. 2014. PMID: 25444830 Free article. Clinical Trial.
Efficacy of an Enterotoxigenic Escherichia coli (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity Score.
Maier N, Grahek SL, Halpern J, Restrepo S, Troncoso F, Shimko J, Torres O, Belkind-Gerson J, Sack DA, Svennerholm AM, Gustafsson B, Sjöstrand B, Carlin N, Bourgeois AL, Porter CK. Maier N, et al. Among authors: gustafsson b. Microorganisms. 2023 Sep 27;11(10):2414. doi: 10.3390/microorganisms11102414. Microorganisms. 2023. PMID: 37894071 Free PMC article.
722 results